Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

Bagsværd, Denmark, 12 December 2025 – Today, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy^® (semaglutide 7.2 mg), bringing it a step closer to offering individuals with obesity in the EU a new Wegovy^® option for even greater weight loss. The new dose of Wegovy^® has demonstrated an average weight loss of 20.7% at 72 weeks, in people with obesity who do not have diabetes.^1* These substantial weight loss results complement the already established health benefits of Wegovy^® in obesity-related complications, including significant reduction in the risk of cardiovascular events such as heart attack and stroke, and reduction in pain from knee osteoarthritis.^2,3